i2O Therapeutics
5 articles about i2O Therapeutics
-
Rapport Therapeutics tops this year’s list with $250 million in Series A and B financing in just six months.
-
Thursday’s FDA advisory committee rejection is the latest regulatory defeat for the company’s drug-device combo. The panel found that the benefits of the treatment did not outweigh its risks.
-
i2o Therapeutics Names Kurt Graves Chairman and CEO, Announces Corporate Updates
8/28/2023
i2o Therapeutics, Inc. announced the appointment of Kurt Graves as Chairman, President and CEO.
-
i2O Therapeutics Announces Research Collaboration and Option Agreement with Janssen to Investigate the Oral Delivery of Macromolecules
1/6/2022
i2O Therapeutics, a developer of oral biologic products based on its proprietary ionic liquid platform, today announced a collaboration and option agreement with Janssen Biotech, Inc., for Janssen Research & Development to evaluate the use of ionic liquid technology for the oral delivery of macromolecules.
-
i2O Therapeutics Announces Research Collaboration with Sanofi to Enable Oral Delivery of Nanobody-based Medicines
2/10/2021
i2O Therapeutics , developers of a platform for oral delivery of traditionally injectable biological drugs, announced today a research collaboration with Sanofi to investigate the oral delivery of Sanofi's Nanobody ® -based medicines, which are currently administered through intravenous or subcutaneous injections. Nanobodies - propr